Shire Falls Most Since June on Adderall XR Competition

Shire Plc, the world’s largest maker of drugs for attention-deficit hyperactivity disorder, fell the most in almost eight months after its once-best-selling Adderall XR treatment got a new generic competitor.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.